We offer a range of translational-based solutions, customized for your pre-clinical and clinical programs. These offerings are all centered around our proven and validated BIOiSIMTM platform for small molecules, large molecules, and viruses.
Our models are built on data from thousands of compounds across 7 species, leading to a robustness rarely seen in the industry.
With a focus on human outcomes, the platform has at its core a translability engine that transforms insights across species.
The BIOiSIMTM platform can be used before preclinical animal trial start, allowing earlier insights and savings in expensive outsourced experimentation.
The team employees a continuous improvement process to iterate on data stability, improve models, and provide an always up-to-date software service.
VSL has shown that the best models are developed by using a hybrid mixed-model approach to drug insights, leading to greater accuracy and scalability.
The flexibility of the platform and generations of customer-ready tools allows for development of custom models and validations within weeks.
VeriSIM has developed a platform that integrates machine learning with robust models of in vivo pharmacokinetics and pharmacodynamics, enabling faster model development, more accurate prediction, and higher scalability.
We leverage existing datasets of physiological outputs from different species to train a model that is physiologically-relevant and translatable across different experimental conditions.
With our framework, we can quickly develop custom, specific models.
We simulate various routes of administrations such as IV, oral, and transdermal and others.
Validated with both FDA and proprietary compounds.
Our platform is cloud-based and generates predictions in seconds.
We are always adding new functionality and expanding the domain of applicability.
Our model extracts conclusions from complex and convoluted data.
Speak to one of our experts today